Corpus Intelligence IC Memo — STRINGFELLOW MEMORIAL HOSPITAL 2026-04-26 07:38 UTC
IC Memo — STRINGFELLOW MEMORIAL HOSPITAL
Investment Committee Memorandum | AL | 125 beds | Grade C | EBITDA uplift $2.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

STRINGFELLOW MEMORIAL HOSPITAL

CCN 010038 | CALHOUN, AL | 125 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

STRINGFELLOW MEMORIAL HOSPITAL is a 125-bed under-performing / distressed in CALHOUN, AL with $30.9M in net patient revenue and a -26.5% operating margin. The hospital serves a payer mix of 31.0% Medicare, 19.8% Medicaid, and 49.2% commercial.

Thesis: Undervalued. Our ML models identify $2.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -26.5% to -19.1% (+736bps).

Net Revenue HCRIS$30.9M
Current EBITDA COMPUTED$-8.2M
Operating Margin COMPUTED-26.5%
Occupancy HCRIS24.6%
Revenue / Bed COMPUTED$247K
Net-to-Gross HCRIS6.9%
Distress Probability ML57.0%

2. Market Context & Competitive Position

115
AL Hospitals
-8.5%
State Median Margin
33
Comparable Hospitals

AL has 115 Medicare-certified hospitals with a median operating margin of -8.5%. The target's margin of -26.5% places it below the state median. Among 33 size-comparable peers (62-250 beds), the median margin is -2.3%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (62-250), prioritizing same-state peers. 33 hospitals in the comp set.

HospitalStateBedsRevenueMargin
STRINGFELLOW MEMORIAL HOSPITAL (Target)AL125$30.9M-26.5%
USA HEALTH UNIVERSITY HOSPITALAL242$348.5M-6.4%
NORTH ALABAMA MEDICAL CENTERAL223$259.5M0.5%
CRESTWOOD MEDICAL CENTERAL164$258.9M14.6%
THOMAS HOSPITALAL164$244.7M6.2%
FLOWERS HOSPITALAL193$235.5M14.2%
USA CHILDRENS AND WOMENS HOSPIAL249$228.8M-0.3%
SPRINGHILL MEMORIAL HOSPITALAL179$216.2M-3.8%
MARSHALL MEDICAL CENTERS SOUTHAL178$186.9M-6.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$649K+210bp18mo
Cost to Collect4.5%2.5%$618K+200bp12mo
Denial Rate Reduction12.0%6.5%$612K+198bp12mo
A/R Days Reduction5200.0%3800.0%$376K+122bp9mo
Clean Claim Rate88.0%96.0%$20K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$649K
Cost to Collect
$618K
Denial Rate Reduction
$612K
A/R Days Reduction
$376K
Clean Claim Rate
$20K
Total EBITDA Uplift$2.3M
Current EBITDA$-8.2M
+ RCM Uplift+$2.3M
Pro Forma EBITDA$-5.9M
Current Margin-26.5%
Pro Forma Margin-19.1%
WC Released (1x)$1.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-12.6M$-31.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-12.6M$-38.4M0.00x-100.0%
Bull Case9.0x11.0x$-11.3M$-35.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-11.3M$-41.5M0.00x-100.0%
Bear Case11.0x10.0x$-13.8M$-38.5M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-13.8M$-46.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 24.6%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 57.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 33 hospitals with 62-250 beds
  • Same-state prioritization (n=34)
  • Comp margins: P25=-10.3% / P50=-2.3% / P75=6.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.